The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network
Open accessAbstract
Hypertensive patients with clinical blood pressure (BP) uncontrolled on ≥3 antihypertensive medications (ie, apparent treatment-resistant hypertension [aTRH]) comprise ≈28% to 30% of all uncontrolled patients in the United States. However, the proportion receiving these medications in optimal doses is unknown; aTRH is used because treatment adherence and measurement artifacts were not available in electronic record data from our >200 community-based clinics Outpatient Quality Improvement Network. This study sought to define the proportion of uncontrolled hypertensives with aTRH on optimal regimens and clinical factors associated with optimal therapy. During 2007–2010, 468 877 hypertensive patients met inclusion criteria. BP <140/<90 mm Hg defined control. Multivariable logistic regression was used to assess variables independently associated with optimal therapy (prescription of diuretic and ≥2 other BP medications at ≥50% of maximum recommended hypertension doses). Among 468 877 hypertensives, 147 635 (31.5%) were uncontrolled; among uncontrolled hypertensives, 44 684 were prescribed ≥3 BP medications (30.3%), of whom 22 189 (15.0%) were prescribed optimal therapy. Clinical factors independently associated with optimal BP therapy included black race (odds ratio, 1.40 [95% confidence interval, 1.32–1.49]), chronic kidney disease (1.31 [1.25–1.38]), diabetes mellitus (1.30 [1.24–1.37]), and coronary heart disease risk equivalent status (1.29 [1.14–1.46]). Clinicians more often prescribe optimal therapy for aTRH when cardiovascular risk is greater and treatment goals lower. Approximately 1 in 7 of all uncontrolled hypertensives and 1 in 2 with uncontrolled aTRH are prescribed ≥3 BP medications in optimal regimens. Prescribing more optimal pharmacotherapy for uncontrolled hypertensives including aTRH, confirmed with out-of-office BP, could improve hypertension control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based13–16 and 15% to 18% of clinic-based reports.17–20”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y., Hendriksen, S. M., Kusek, J. W., & Lente, F. V. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,726
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S. M., Prosek, J. M., Nádasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,392
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
Self-citationUS trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Self-citationThe J-Curve Phenomenon in Hypertension
Kang, Y., & Wang, J. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,551
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.189141 · Cited by 1,416
Self-citationde la Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., de la Cruz, J. J., Armario, P., Oliveras, A., & Ruilope, L. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168948 · Cited by 809
Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
Appel, L. J., Wright, J. T., Greene, T., Agodoa, L. Y. C., Astor, B. C., Bakris, G. L., Cleveland, W. H., Charleston, J. B., Contreras, G. N., Faulkner, M. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910975 · Cited by 719
Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Egan, B. M., Zhao, Y., Axon, R. N., Brzezinski, W. A., & Ferdinand, K. C. (2011) · Circulation · doi:10.1161/circulationaha.111.030189 · Cited by 599
Self-citationManagement of High Blood Pressure in Blacks
Flack, J. M., Sica, D. A., Bakris, G. L., Brown, A. L., Ferdinand, K. C., Grimm, R. H., Hall, W. D., Jones, W. E., Kountz, D. S., Lea, J. P., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.152892 · Cited by 450
PIERDOMENICO, S., LAPENNA, D., BUCCI, A., DITOMMASO, R., DIMASCIO, R., MANENTE, B., CALDARELLA, M., NERI, M., CUCCURULLO, F., & MEZZETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.05.014 · Cited by 409
Statin-Sensitive Dysregulated AT1 Receptor Function and Density in Hypercholesterolemic Men
Nickenig, G., Bäumer, A. T., Temur, Y., Kebben, D., Jockenhövel, F., & Böhm, M. (1999) · Circulation · doi:10.1161/01.cir.100.21.2131 · Cited by 394
Continuation of initial antihypertensive medication after 1 year of therapy.
Bloom, B. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80130-6 · Cited by 324
Taler, S. J., Textor, S. C., & Augustine, J. A. (2002) · Hypertension · doi:10.1161/01.hyp.0000016176.16042.2f · Cited by 307
Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension
Salles, G. F., Cardoso, C. R. L., & Muxfeldt, E. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2340 · Cited by 293
Racial Differences in Blood Pressure Control: Potential Explanatory Factors
Bosworth, H. B., Dudley, T. K., Olsen, M. K., Voils, C. I., Powers, B. J., Goldstein, M. K., & Oddone, E. Ž. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.019 · Cited by 280
Initial Monotherapy and Combination Therapy and Hypertension Control the First Year
Egan, B. M., Bandyopadhyay, D., Shaftman, S. R., Wagner, C. S., Zhao, Y., & Yu-Isenberg, K. S. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.194167 · Cited by 250
Self-citationCeral, J., Habrdová, V., Voříšek, V., Bima, M., Pelouch, R., & Solař, M. (2010) · Hypertension Research · doi:10.1038/hr.2010.183 · Cited by 170
Egan, B. M., Basile, J., Rehman, S. U., Davis, P. B., Grob, C. H., RIEHLE, J., Walters, C., Lackland, D. T., Merali, C., Sealey, J. E., et al. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.63 · Cited by 131
Self-citationAntihypertensive medication adherence and subsequent healthcare utilization and costs.
Pittman, D. G., Tao, Z., Chen, W., & Stettin, G. (2010) · PubMed · Cited by 130
Progression Is Accelerated From Prehypertension to Hypertension in Blacks
Selassie, A., Wagner, C. S., Laken, M. L., Ferguson, M. L., Ferdinand, K. C., & Egan, B. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.177410 · Cited by 124
Self-citationOrrico, K. B. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.7.626 · Cited by 103
Mejia, A. D., Egan, B. M., Schork, N. J., & Zweifler, A. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-4-270 · Cited by 81
Self-citationPrevalence and Correlates of Low Medication Adherence in Apparent Treatment‐Resistant Hypertension
Irvin, M. R., Shimbo, D., Mann, D. M., Reynolds, K., Krousel-Wood, M. A., Limdi, N. A., Lackland, D. T., Calhoun, D. A., Oparil, S., & Muntner, P. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00690.x · Cited by 80
Self-citationPharmacogenomics of blood pressure response to antihypertensive treatment
Mellen, P. B., & Herrington, D. M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000173510.52987.68 · Cited by 65
Kjeldsen, S. E., Jamerson, K., Bakris, G. L., Pitt, B., Dahlöf, B., Velazquez, E. J., Gupte, J., Staikos-Byrne, L., Hua, T. A., Shi, V. C., et al. (2008) · Blood Pressure · doi:10.1080/08037050801972857 · Cited by 52
Use of Aldosterone Antagonists in Resistant Hypertension
Calhoun, D. A. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.02.002 · Cited by 52
Self-citationEgan, B. M., & Zhao, Y. (2012) · Journal of Clinical Hypertension · doi:10.1111/jch.12057 · Cited by 40
Self-citationEffects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Sarafidis, P. A., Kanaki, A., & Lasaridis, A. N. (2007) · Current Vascular Pharmacology · doi:10.2174/157016107780368307 · Cited by 14
Egan, B. M., Shaftman, S. R., Wagner, C. S., Bandyopadhyay, D., & Szymanski, K. A. (2012) · PubMed · Cited by 12
Self-citationHypertension Control in African-American Patients with Chronic Kidney Disease
Ingelfinger, J. R. (2010) · New England Journal of Medicine · doi:10.1056/nejme1007783 · Cited by 9
Kjeldsen, S. E., Jamerson, K., Bakris, G. L., Pitt, B., Dahlöf, B., Velazquez, E. J., Hua, T. A., Kelly, R. Y., Zappe, D., Hester, A., et al. (2011) · Blood Pressure · doi:10.3109/08037051.2011.598699 · Cited by 9
Cited by
Sorted by citations
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Self-citationTrends in Blood Pressure Among Adults With Hypertension
Yoon, S. S., Gu, Q., Nwankwo, T., Wright, J. D., Hong, Y., & Burt, V. L. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04012 · Cited by 260
Treatment of Resistant and Refractory Hypertension
Acelajado, M. C., Hughes, Z. H., Oparil, S., & Calhoun, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.118.312156 · Cited by 226
Self-citationMadhur, M. S., Elijovich, F., Alexander, M. R., Pitzer, A. L., Ishimwe, J., Beusecum, J. P. V., Patrick, D. M., Smart, C. D., Kleyman, T. R., Kingery, J. R., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.318052 · Cited by 218
Metadata
- Authors
- Egan, B. M., Zhao, Y., Li, J., Brzezinski, W. A., Todoran, T. M., Brook, R. D., & Calhoun, D. A.
- Affiliations
- Medical University of South Carolina (US)
- Venue
- Hypertension
- Published
- 2013-10
- Volume
- 62
- Issue
- 4
- Pages
- 691-697
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- PMC
- PMC4066303
- OpenAlex
- W2142011051
- Cited by
- 158
- References
- 37
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 13 · 2023: 16 · 2022: 12 · 2021: 6 · 2020: 10 · 2019: 8 · 2018: 12 · 2017: 14 · 2016: 21 · 2015: 16 · 2014: 22 · 2013: 3
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Heart, Lung, and Blood Institute (R34HL105880, R01HL091841, HL091841, HL105880)
- National Institute of Neurological Disorders and Stroke (NS058728, U01NS058728)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- apparent treatment-resistant hypertension, uncontrolled hypertension, office blood pressure, diuretics, chronic kidney disease, diabetes mellitus, coronary heart disease risk, racial disparities, hypertension control, community clinics
- MeSH terms
- Aged, Antihypertensive Agents, Black or African American, Blood Pressure, Blood Pressure Determination, Community Health Services, Female, Humans, Hypertension, Male, Middle Aged, Risk Factors, United States, Prevalence, Treatment Failure, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
